Search

Your search keyword '"Russell, Beth"' showing total 341 results
Start Over Author "Russell, Beth" Search Limiters Available in Library Collection
341 results on '"Russell, Beth"'

1. Using real world evidence to assess clinical outcomes in patients diagnosed with bladder cancer

Author

Russell, Beth and Van Hemelrijck, Mieke

Subjects
616.99
Abstract

Introduction: The current 10-year survival rate for patients with bladder cancer stands at around 50%. It is imperative that the prognostic value of factors surrounding treatments and demographics for bladder cancer patients are identified to allow for improvements in these survival rates. To that end, this thesis consists of the following three projects: 1. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: an investigation on survival; 2. Effect of a delay in radical treatment on survival in bladder cancer patients; 3. A mediation analysis to explain socio-economic differences in bladder cancer survival. Methods: This thesis utilised a mixture of analyses to investigate the three projects which were carried out using both single-centre and nationwide data from two databases: The Guy’s and St Thomas’ Hospital cystectomy database, and the BladderBaSe. Project 1 utilised Cox regression models on data from both databases for all patients with clinical T2-T4, N0, M0 disease. Propensity score matching was also carried out for the BladderBaSe data. The second project was carried out through a systematic review and meta-analyses to collate as much information regarding delay to cystectomy as possible. The second half of this project consisted of a survival analyses conducted on data extracted from the BladderBaSe. Cox proportional hazards models were carried out to assess the impact of a longer time between TURBT and either NAC or radical cystectomy. Project 3 also consisted of a systematic review and was followed by both survival and mediation analyses in order to first ascertain a relationship between SES and survival, and then to disentangle the heterogeneity in these survival outcomes by identifying any potential mediators of the relationship. Results: Project 1: From the 944 patients analysed in the BladderBaSe study, those who had received NAC had higher 5-year survival proportions and decreased risk of both overall and bladder cancer-specific death (HR=0.71, 95% CI: 0.52–0.97 and HR=0.67, 95% CI: 0.48–0.94), respectively, as compared to patients who did not receive NAC. The PS matched cohort showed similar estimates, but with larger statistical uncertainty (Overall death: HR=0.76, 95% CI: 0.53–1.09 and bladder cancer-specific death: HR=0.73, 95% CI: 0.50–1.07). In the Guy’s and St. Thomas cystectomy data, an absolute survival benefit of 18% was observed in the NAC patients (n=62) when compared to those who did not receive NAC (n=172). The Cox models also revealed a reduced risk of death in the NAC patients (HR=0.57, 95% CI: 0.36-0.92), compared to those who did not receive NAC. Project 2: The systematic review identified nineteen studies which were eligible for inclusion (17,532 patients). Ten of these studies were included in the meta-analyses for which a longer delay between bladder cancer diagnosis and radical cystectomy resulted in a pooled hazard ratio of 1.34 (95% CI: 1.18-1.53) for overall death. For delay between TURBT and cystectomy, the pooled hazard ratio was 1.18 (95% CI: 0.99-1.41) for overall death. A pooled hazard ratio of 1.04 (95%CI: 0.93-1.16) was calculated for a longer delay between NAC and radical cystectomy. The BladderBaSe study identified no clear pattern of association between patients who experienced a longer time between TURBT and radical cystectomy (n=2,160 patients). The Cox models suggested an increased risk of bladder cancer-specific death in patients who had a longer time between TURBT and receiving NAC (HR=3.45, 95% CI: 1.11-10.73). Project 3: The AFT models revealed patients (both NMIBC and MIBC) with a medium or high SES had an increased survival both overall and bladder cancer-specific when compared to patients with a low SES (n=37,755 patients). In the NMIBC patients, Charlson Comorbidity Index was found to mediate this relationship by 10% (percentage of the total effect explained by mediator) and hospital type by 4%. The time from referral to TURBT was a considerable mediator (14%) in the MIBC patients only. The subsequent systematic review identified a wealth of studies investigating the relationship between each of the proposed mediators with survival in bladder cancer patients. There was however found to be a paucity in studies investigating the associations between said mediators and SES in bladder cancer specifically. Conclusions: This thesis has used real world evidence to help explore factors which affect the survival of bladder cancer patients. The effect of NAC has been extensively studied in RCTs but evidence using observational data is somewhat lacking. However, results from this thesis suggest its regimen imposes a survival benefit in patients even in a real world setting and future studies should focus on identifying exactly which patients benefit most. This thesis has also highlighted the complexity of the relationship between treatment delay and survival for those in need of radical cystectomy. Though the meta-analyses imply a negative impact on survival when radical treatment is delayed, the effect of this delay in patients receiving NAC requires more investigation. Finally, the associations observed between SES and survival using Swedish data for the first time are in line with existing literature. The current results suggest this relationship is contributed to by several factors. However, as the theoretical causal relationship could not be fully explained by the proposed mediators, more factors still need to be identified as further potential mediators. To the best of our knowledge this is the first time mediation analysis has been used to investigate the association between SES and survival in bladder cancer. This thesis has benefitted from the use of real word data to investigate questions not possible through the use of RCTS (i.e. the effect of a delay in cystectomy). Overall, it is hoped the results from this thesis can be used to build upon the knowledge of prognostic factors for patients with bladder cancer. Moreover, the results identify a need for a standardization of data collection methods for observational databases.

Published
2020

2. Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave

Author

Russell, Beth, Moss, Charlotte, Monroy-Iglesias, Maria, Roberts, Graham, Dickinson, Harvey, Haire, Kate, Innes, Kathryn, Mulji-Shah, Bansi, Castell, Fiona, Al-Salihi, Omar, Lei, Mary, Francis, Angela, Dann, Bill, Jogia, Vikash, Hamid, Hisham, Challacombe, Ben, Simo, Ricard, Fraser, Stephanie, Gousis, Charalampos, Sawyer, Elinor, Tsotra, Eirini, Roca, Jose, Khan, Muhammad, Josephs, Debra, Enting, Deborah, Van Hemelrijck, Mieke, Harris, Victoria, and Dolly, Saoirse

Published
2022
Full Text
View/download PDF

4. Real-world data evaluating Guy’s rapid diagnostic clinic as an alternate pathway for patients with FIT levels below 10

Author

Monroy-Iglesias, Maria Jose, primary, Martin, Sabine, additional, Cargaleiro, Carlos, additional, Jones, Geraint, additional, Steward, Lindsay, additional, Murtagh, Colette, additional, Bruno, Flaminia, additional, Millwaters, Juliet, additional, Schizas, Alexis, additional, Watson, Harriet, additional, Haire, Anna, additional, Haire, Kate, additional, Moss, Charlotte Louise, additional, Russell, Beth, additional, Srirajaskanthan, Raj, additional, Van Hemelrijck, Mieke, additional, and Dolly, Saoirse, additional

Published
2024
Full Text
View/download PDF

5. Survivorship Data in Prostate Cancer:Where Are We and Where Do We Need To Be?

Author

Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, Van Hemelrijck, Mieke, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Abstract

Cancer survivorship was recently identified as a prostate cancer (PCa) research priority by PIONEER, a European network of excellence for big data in PCa. Despite being a research priority, cancer survivorship lacks a clear and agreed definition, and there is a distinct paucity of patient-reported outcome (PRO) data available on the subject. Data collection on cancer survivorship depends on the availability and implementation of (validated) routinely collected patient-reported outcome measures (PROMs). There have been recent advances in the availability of such PROMs. For instance, the European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) is developing survivorship questionnaires. This provides an excellent first step in improving the data available on cancer survivorship. However, we propose that an agreed, standardised definition of (prostate) cancer survivorship must first be established. Only then can real-world data on survivorship be collected to strengthen our knowledge base. With more men than ever surviving PCa, this type of research is imperative to ensure that the quality of life of these men is considered as much as their quantity of life. Patient summary: As there are more prostate cancer survivors than ever before, research into cancer survivorship is crucial. We highlight the importance of such research and provide recommendations on how to carry it out. The first step should be establishing agreement on a standardised definition of survivorship. From this, patient-reported outcome measures can then be used to collect important survivorship data.

Published
2024

6. Anxiety and depression in patients with non-site-specific cancer symptoms: data from a rapid diagnostic clinic.

Author

Monroy-Iglesias, Maria J., Russell, Beth, Martin, Sabine, Fox, Louis, Moss, Charlotte, Bruno, Flaminia, Millwaters, Juliet, Steward, Lindsay, Murtagh, Colette, Cargaleiro, Carlos, Bater, Darren, Lavelle, Grace, Simpson, Anna, Onih, Jemima, Haire, Anna, Reeder, Clare, Jones, Geraint, Smith, Sue, Santaolalla, Aida, and Van Hemelrijck, Mieke

Subjects
MENTAL depression, ANXIETY, MACHINE learning, CANCER patients, ANXIETY disorders, SUPPORT vector machines
Abstract

Background: Rapid diagnostic clinics (RDCs) provide a streamlined holistic pathway for patients presenting with non-site specific (NSS) symptoms concerning of malignancy. The current study aimed to: 1) assess the prevalence of anxiety and depression, and 2) identify a combination of patient characteristics and symptoms associated with severe anxiety and depression at Guy's and St Thomas' Foundation Trust (GSTT) RDC in Southeast London. Additionally, we compared standard statistical methods with machine learning algorithms for predicting severe anxiety and depression. Methods: Patients seen at GSTT RDC between June 2019 and January 2023 completed the General Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-8) questionnaires, at baseline. We used logistic regression (LR) and 2 machine learning (ML) algorithms (random forest (RF), support vector machine (SVM)) to predict risk of severe anxiety and severe depression. The models were constructed using a set of sociodemographic and clinical variables. Results: A total of 1734 patients completed GAD-7 and PHQ-8 questionnaires. Of these, the mean age was 59 years (Standard Deviation: 15.5), and 61.5% (n:1067) were female. Prevalence of severe anxiety (GAD-7 score ≥15) was 13.8% and severe depression (PHQ-8 score≥20) was 9.3%. LR showed that a combination of previous mental health condition (PMH, Adjusted Odds Rario (AOR) 3.28; 95% confidence interval (CI) 2.36-4.56), symptom duration >6 months (AOR 2.20; 95%CI 1.28-3.77), weight loss (AOR 1.88; 95% CI 1.362.61), progressive pain (AOR 1.71; 95%CI 1.26-2.32), and fatigue (AOR 1.36; 95%CI 1.01-1.84), was positively associated with severe anxiety. Likewise, a combination PMH condition (AOR 3.95; 95%CI 2.17-5.75), fatigue (AOR 2.11; 95%CI 1.47-3.01), symptom duration >6 months (AOR 1.98; 95%CI 1.06-3.68), weight loss (AOR 1.66; 95%CI 1.13-2.44), and progressive pain (AOR 1.50; 95%CI 1.04-2.16), was positively associated with severe depression. LR and SVM had highest accuracy levels for severe anxiety (LR: 86%, SVM: 85%) and severe depression (SVM: 89%, LR: 86%). Conclusion: High prevalence of severe anxiety and severe depression was found. PMH, fatigue, weight loss, progressive pain, and symptoms >6 months emerged as combined risk factors for both these psychological comorbidities. RDCs offer an opportunity to alleviate distress in patients with concerning symptoms by expediting diagnostic evaluations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. A cohort profile of the Graham Roberts study cohort

Author

Russell, Beth, primary, Leech, Poppy, additional, Wylie, Harriet, additional, Moss, Charlotte Louise, additional, Haire, Anna, additional, Enting, Deborah, additional, Amery, Suzanne, additional, Chatterton, Kathryn, additional, Khan, Muhammad Shamim, additional, Thurairaja, Ramesh, additional, Nair, Rajesh, additional, Malde, Sachin, additional, Smith, Kate, additional, Gillett, Cheryl, additional, Josephs, Debra, additional, Pintus, Elias, additional, Rudman, Sarah, additional, Hughes, Simon, additional, Relton, Clare, additional, and Van Hemelrijck, Mieke, additional

Published
2024
Full Text
View/download PDF

12. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Author

Smith, Emma, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Abbott, Tom, Mastris, Ken, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Fossati, Nicola, Pang, Karl, Campi, Riccardo, Greco, Isabella, Gacci, Mauro, Serni, Sergio, Bjartell, Anders, Lonnerbro, Ragnar, Briganti, Alberto, Crosti, Daniele, Garzonio, Roberto, Gandaglia, Giorgio, Faticoni, Martina, Grant office, Bangma, Chris, Jongerden, Maria, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Lejeune, Stephane, Colette, Laurence, Caputova, Simona, Poli, Delielena, Byrne, Sophie, Fialho, Luz, Rowland, Ashley, Tapela, Neo, Di Flora, Nicola, Apostolidis, Kathi, Lemair, Valerie, De Meulder, Bertrand, Auffray, Charles, Taibi, Nesrine, Hijazy, Ayman, Saporta, Albert, Sun, Kai, Power, Shaun, Zounemat Kermani, Nazanin, van Bochove, Kees, Tafreshiha, Azadeh, Bernini, Chiara, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Tripathee, Sheela, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Gasi Tandefelt, Delila, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Tames Grijalva, Monica, Evans-Axelsson, Susan, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Waldeck, Reg, Bruno, Amanda, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Steinbeisser, Carl, Maass, Monika, Torremante, Patrizia, Dochy, Emmanuelle, Pisa, Federica, Voss, Marc Dietrich, Papineni, Kishore, Wang-silvanto, Jing, Snijder, Robert, Wang, Xuewei, Lambrecht, Mark, Wolfinger, Russ, Eid, Sherinne, Palanisamy, Soundarya, Haque, Samiul, Antoni, Laurent, Servan, Angela, Pascoe, Katie, Robinson, Paul, Lencart, Joana, Jaton, Bertrand, Turunen, Heidi, Kilkku, Olavi, Pohjanjousi, Pasi, Voima, Olli, Nevalaita, Liina, Punakivi, Keijo, Seager, Sarah, Ratwani, Shilpa, Grzeslak, Katarzyna, Brash, James, Longden-Chapman, Elaine, Burke, Danny, Licour, Muriel, Payne, Sarah, Yong, Alan, Lujan, Flavia, Le Mare, Sophia, Hendrich, Jan, Bussmann, Michael, Juckeland, Kotik, Reich, Christian, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Published
2024
Full Text
View/download PDF

14. Real World Data Studies of Antineoplastic Drugs: How Can They Be Improved to Steer Everyday Use in the Clinic?

Author

George,Gincy, Russell,Beth, Rigg,Anne, Coolen,Anthony CC, Van Hemelrijck,Mieke, George,Gincy, Russell,Beth, Rigg,Anne, Coolen,Anthony CC, and Van Hemelrijck,Mieke

Abstract

Gincy George,1 Beth Russell,1 Anne Rigg,2 Anthony CC Coolen,3 Mieke Van Hemelrijck1 1Translational Oncology and Urology Research, King’s College London, London, UK; 2Guy’s Cancer Centre, Guy’s and St Thomas NHS Foundation Trust, London, UK; 3Department of Biophysics, Radboud University, Nijmegen, the NetherlandsCorrespondence: Gincy George, King’s College London, Translational Oncology and Urology Research, London, SE1 9RT, United Kingdom, Email gincy.e.george@kcl.ac.ukAbstract: There is a growing interest in real world evidence when developing antineoplastic drugs owing to the shorter length of time and low costs compared to randomised controlled trials. External validity of studies in the regulatory phase can be enhanced by complementing randomised controlled trials with real world evidence. Furthermore, the use of real world evidence ensures the inclusion of patients often excluded from randomised controlled trials such as the elderly, certain ethnicities or those from certain geographical areas. This review explores approaches in which real world data may be integrated with randomised controlled trials. One approach is by using big data, especially when investigating drugs in the antineoplastic setting. This can even inform artificial intelligence thus ensuring faster and more precise diagnosis and treatment decisions. Pragmatic trials also offer an approach to examine the effectiveness of novel antineoplastic drugs without evading the benefits of randomised controlled trials. A well-designed pragmatic trial would yield results with high external validity by employing a simple study design with a large sample size and diverse settings. Although randomised controlled trials can determine efficacy of antineoplastic drugs, effectiveness in the real world may differ. The need for pragmatic trials to help guide healthcare decision-making led to the development of trials within cohorts (TWICs). TWICs make use of cohorts to conduct multiple randomised controlle

Published
2023

15. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012–2018:A Retrospective, Population-Based Study

Author

White, Benjamin E., Russell, Beth, Remmers, Sebastiaan, Rous, Brian, Chandrakumaran, Kandiah, Wong, Kwok F., Van Hemelrijck, Mieke, Srirajaskanthan, Rajaventhan, Ramage, John K., White, Benjamin E., Russell, Beth, Remmers, Sebastiaan, Rous, Brian, Chandrakumaran, Kandiah, Wong, Kwok F., Van Hemelrijck, Mieke, Srirajaskanthan, Rajaventhan, and Ramage, John K.

Abstract

Pre-clinical studies have suggested sex hormone signalling pathways may influence tumorigenesis in neuroendocrine neoplasia (NEN). We conducted a retrospective, population-based study to compare overall survival (OS) between males and females with NEN. A total of 14,834 cases of NEN diagnosed between 2012 and 2018, recorded in England’s National Cancer Registry and Analysis Service (NCRAS), were analysed. The primary outcome was OS with 5 years maximum follow-up. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Appendiceal, pulmonary and early-stage NEN were most commonly diagnosed in females; stomach, pancreatic, small intestinal, colonic, rectal and later-stage NEN were more often diagnosed in males. Females displayed increased survival irrespective of the stage, morphology or level of deprivation. On average, they survived 3.62 (95% CI 1.73–5.90) to 10.26 (6.6–14.45) months longer than males; this was statistically significant in NEN of the lung, pancreas, rectum and stomach (p < 0.001). The stage mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. The reasons underlying these differences are not yet understood. Overall, females diagnosed with NEN tend to survive longer than males, and the stage at presentation only partially explains this. Future research, as well as prognostication and treatment, should consider sex as an important factor.

Published
2023

16. 'The Fruits of Intellectual Labor': International Student Views of Intellectual Property

Author

Datig, Ilka and Russell, Beth

Abstract

In this paper, we report on the results of a study conducted at New York University Abu Dhabi in the fall of 2013. Our goal in the study was to gain a global college student perspective on issues related to intellectual property, including copyright and plagiarism. We found that, contrary to popular opinion, most of our students have a solid understanding of the nature of intellectual property rights, as interpreted within the North American higher education community. In addition, the majority of our students view violations of intellectual property rights and norms, such as plagiarism, negatively.

Published
2015
Full Text
View/download PDF

20. Clinical outcomes of anterior prostate cancers treated with robotic assisted radical prostatectomy

Author

Saghir, Reyan, primary, Russell, Beth, additional, Kum, Francesca, additional, Darwish, Raef, additional, Deane, Jude, additional, Allen, Christopher, additional, Rizwi, Hira, additional, Saghir, Noman, additional, Mayor, Nikhil, additional, Cathcart, Paul, additional, Dasgupta, Prokar, additional, Popert, Rick, additional, Brown, Christian, additional, and Challacombe, Ben, additional

Published
2022
Full Text
View/download PDF

24. Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer

Author

Russell, Beth, Liedberg, Fredrik, Hagberg, Oskar, Ullen, Anders, Soderkvist, Karin, Strock, Viveka, Aljabery, Firas, Gardmark, Truls, Jerlstrom, Tomas, Sherif, Amir, Holmberg, Lars, Bryan, Richard T., Enting, Deborah, Van Hemelrijck, Mieke, Russell, Beth, Liedberg, Fredrik, Hagberg, Oskar, Ullen, Anders, Soderkvist, Karin, Strock, Viveka, Aljabery, Firas, Gardmark, Truls, Jerlstrom, Tomas, Sherif, Amir, Holmberg, Lars, Bryan, Richard T., Enting, Deborah, and Van Hemelrijck, Mieke

Abstract

Introduction and objectives Bladder cancer is primarily a disease of older age and little is known about the differences between patients diagnosed with bladder cancer at a younger versus older age. Our objectives were to compare bladder cancer specific survival in patients aged <50 versus those aged 50–70 at time of diagnosis. Materials and methods The Swedish bladder cancer database provided data on patient demographics, clinical characteristics and treatments for this observational study. Cox proportional hazard regression models were adjusted for appropriate variables. All analyses were stratified by disease stage (non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Furthermore, we compared the frequency of lower urinary tract infections within 24 months prior to bladder cancer diagnosis by sex and age groups. Results The study included 15,452 newly-diagnosed BC patients (1997-2014); 1,207 (8%) patients were <50 whilst 14,245 (92%) were aged 50-70. Patients aged <50 at diagnosis were at a decreased risk of bladder cancer death (HR = 0.82, 95%CI: 0.68-0.99) compared to those aged 50-70. When stratified by non-muscle-invasive and muscle-invasive bladder cancer, this association remained in non-muscle-invasive patients only (<50, HR = 0.43, 95% CI: 0.28-0.64). The frequency of lower urinary tract infection diagnoses did not differ between younger and older patients in either men or women. Conclusions Patients diagnosed with non-muscle-invasive bladder cancer when aged <50 are at decreased risk of bladder cancer-specific death when compared to their older (50-70) counterparts. These observations raise relevant research questions about age-related differences in diagnostic procedures, clinical decision-making and, not least, potential differences in tumour biology.

Published
2022
Full Text
View/download PDF

25. Secondary Treatment for Men with Localized Prostate Cancer:A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform

Author

Beyer, Katharina, Straten, Vera, Remmers, Sebastiaan, Maclennan, Steven, Maclennan, Sara, Gandaglia, Giorgio, Willemse, Peter Paul M., Herrera, Ronald, Omar, Muhammad Imran, Russell, Beth, Huber, Johannes, Kreuz, Markus, Asiimwe, Alex, Abbott, Tom, Briganti, Alberto, Hemelrijck, Mieke Van, Roobol, Monique J., Beyer, Katharina, Straten, Vera, Remmers, Sebastiaan, Maclennan, Steven, Maclennan, Sara, Gandaglia, Giorgio, Willemse, Peter Paul M., Herrera, Ronald, Omar, Muhammad Imran, Russell, Beth, Huber, Johannes, Kreuz, Markus, Asiimwe, Alex, Abbott, Tom, Briganti, Alberto, Hemelrijck, Mieke Van, and Roobol, Monique J.

Abstract

Introduction: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change. Methods: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT). Results: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively. Conclusion: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).

Published
2022

26. Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform

Author

MS Urologische Oncologie, Cancer, Beyer, Katharina, Straten, Vera, Remmers, Sebastiaan, MacLennan, Steven, MacLennan, Sara, Gandaglia, Giorgio, Willemse, Peter-Paul M, Herrera, Ronald, Omar, Muhammad Imran, Russell, Beth, Huber, Johannes, Kreuz, Markus, Asiimwe, Alex, Abbott, Tom, Briganti, Alberto, Van Hemelrijck, Mieke, Roobol, Monique J, The Prias Consortium, The Erspc Rotterdam Study Group, The Pioneer Consortium, MS Urologische Oncologie, Cancer, Beyer, Katharina, Straten, Vera, Remmers, Sebastiaan, MacLennan, Steven, MacLennan, Sara, Gandaglia, Giorgio, Willemse, Peter-Paul M, Herrera, Ronald, Omar, Muhammad Imran, Russell, Beth, Huber, Johannes, Kreuz, Markus, Asiimwe, Alex, Abbott, Tom, Briganti, Alberto, Van Hemelrijck, Mieke, Roobol, Monique J, The Prias Consortium, The Erspc Rotterdam Study Group, and The Pioneer Consortium

Published
2022

27. The experience of UK patients with bladder cancer during the second wave of the COVID‐19 pandemic

Author

Russell, Beth, primary, Spencer‐Bowdage, Sarah, additional, Rigby, Jeannie, additional, O'Kelly, Jackie, additional, Kelly, Phil, additional, Page, Mark, additional, Raw, Caroline, additional, Allchorne, Paula, additional, Harper, Peter, additional, Crew, Jeremy, additional, Kockelbergh, Roger, additional, Knight, Allen, additional, Van Hemelrijck, Mieke, additional, and Bryan, Richard T., additional

Published
2022
Full Text
View/download PDF

29. Scoping review: bladder cancer in Nigeria – what are the gaps in clinical care and research?

Author

Iya, Abdulkarim Muhammad, primary, Beyer, Katharina, additional, Kotecha, Pinky, additional, Kibaru, Joyce, additional, Abdullahi, Muzzammil, additional, Alhassan, Sani Usman, additional, Mustapha, Muhammad Inuwa, additional, Ahmad, Abdullahi, additional, Lawal, Yusuf, additional, Rabiu Ibrahim, Jalo, additional, Aminu, Aliyu, additional, Abubakar, Aisha, additional, Saleh, Abdullahi, additional, Bryan, Richard T, additional, Van Hemelrijck, Mieke, additional, and Russell, Beth, additional

Published
2022
Full Text
View/download PDF

30. The impact of hospital attendance on COVID-19 infection in cancer patients: an assessment of data from Guy's Cancer

Author

Tremble, Kathryn, primary, Fox, Louis, additional, Moss, Charlotte, additional, Russell, Beth, additional, Aljazzaf, Haleema, additional, Higgins, Finola, additional, Dann, Bill, additional, Jogia, Vikash, additional, Roberts, Graham, additional, Rigg, Anne, additional, Dolly, Saoirse, additional, and Van Hemelrijck, Mieke, additional

Published
2022
Full Text
View/download PDF

31. Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

Author

Várnai, Csilla, Palles, Claire, Arnold, Roland, Curley, Helen M., Purshouse, Karin, Cheng, Vinton W. T., Booth, Stephen, Campton, Naomi A., Collins, Graham P., Hughes, Daniel J., Kulasekararaj, Austin G., Lee, Alvin J. X., Olsson-brown, Anna C., Sharma-oates, Archana, Van Hemelrijck, Mieke, Lee, Lennard Y. W., Kerr, Rachel, Middleton, Gary, Cazier, Jean-baptiste, Pugh, Sian, Corrie, Pippa, Bedair, Ahmed, Hewish, Madeleine, Leonard, Pauline, Illingworth, Jack, Hibbs, Stephen, Diamantis, Nicolaos, Massalha, Samah, Fuller, Claire, Usbourne, Caroline, Gilbert, Duncan, Davies, Jennifer, Newsom-davis, Tom, Sharkey, Rachel, Lee, Rebecca, Tivey, Ann, Shotton, Rohan, Griffin, Clare, Horsley, Laura, Shamas, Simon, Sacco, Joseph J, Choudhury, Madbuba, Noble, Jillian, Shaw, Heather, Bolton, Rachel, Ferreira, Ana, Hall, Peter, Ramage, Paul, Bhosle, Jaishree, Massey, Alison, Hill, Michaela, Mukherjee, Leena, Ghaus, Aisha, Derby, Sarah, Brown, Sean, Lowndes, Sarah, Dolly, Saorise, Russell, Beth, Moss, Charlotte, Muller, Daniel, Pillai, Annet, Lowe, Shakeel, Cook, Lucy, Scrase, Christopher, Jyothirmayi, Rema, Board, Ruth, Cornthwaite, Stephanie, Parikh, Shefail, Cattell, Emma, Cox, Nicola, Gault, Abigail, Moody, Sam, Dobeson, Caroline, Baxter, Mark, Roques, Tom, Pawsey, Alexander, Oakes, Roderick, Melcher, Lucinda, Chan, Olivia, Ayers, Sarah, Bowyer, Helen, Althohami, Mohammed, Mittal, Sajjan, Feeney, Laura, Aujayeb, Avinash, Sheikh, Omar, Kathirgamakarthigeyan, Sangary, Woodcock, Victoria, Holt, Francesca, Wyatt, Simon, Topping, Oliver, Tilby, Michael, Bhattacharyya, Madhumita, Burke, Emma, Ellis, Shawn, Chacko, Joseph, Rabbi, Taslima, Rowe, Michael, Sargent, Rebecca, Thirlwell, Christina, Gibson, Jack, Goldstein, Robert, Fittall, Mathew, Gennatas, Spyridon, Okines, Alicia, Best, James, Tillett, Tania, Renninson, Emily, Grumett, Simon, Barrington, Craig, Pettengell, Ruth, Peng, Yingyying, Chackathayil, Julia, Akingboye, Akinfemi, Hollis, Helen, Shin Chin, Ik, Bisht, Vartika, Hartley, Simon, Middleton, Christopher P, Goel, Anshita, Protheroe, Emily, Naksukpaiboon, Paingfan, Anil, Iris, Michell, Joel, D'costa, Jamie, Wu, Anjui, Ottaviani, Diego, Soosaipillai, Gehan, Galazi, Myria, Chopra, Neha, Benafif, Sarah, Sng, Christopher Ct, Wong, Sophia Yn, Scott-brown, Martin, Copson, Ellen, Robinson, Timothy, Hudson, Zoe, Smith, Fiona, Abdulnabi Mohamed, Ali-abdulnabi, Angelakas, Angelos, Eastlake, Leoni, Poon-king, Ashley, Brunner, Clair, Kwan, Amy, Maynard, Alec, Boyce, Hayley, Spurrell, Emma, Peck, Rahul, and Kurec, Bartlomiej

Subjects
Aged, 80 and over, Male, Lung Neoplasms, SARS-CoV-2, COVID-19, General Medicine, Middle Aged, United Kingdom, Cohort Studies, Drug Therapy, Hematologic Neoplasms, Humans, Female, Immunotherapy, Prospective Studies, Registries, Aged
Abstract

Importance Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality.Objective To evaluate whether systemic anticancer treatments (SACTs), tumor subtypes, patient demographic characteristics (age and sex), and comorbidities are associated with COVID-19 mortality.Design, Setting, and Participants The UK Coronavirus Cancer Monitoring Project (UKCCMP) is a prospective cohort study conducted at 69 UK cancer hospitals among adult patients (≥18 years) with an active cancer and a clinical diagnosis of COVID-19. Patients registered from March 18 to August 1, 2020, were included in this analysis.Exposures SACT, tumor subtype, patient demographic characteristics (eg, age, sex, body mass index, race and ethnicity, smoking history), and comorbidities were investigated.Main Outcomes and Measures The primary end point was all-cause mortality within the primary hospitalization.Results Overall, 2515 of 2786 patients registered during the study period were included; 1464 (58%) were men; and the median (IQR) age was 72 (62-80) years. The mortality rate was 38% (966 patients). The data suggest an association between higher mortality in patients with hematological malignant neoplasms irrespective of recent SACT, particularly in those with acute leukemias or myelodysplastic syndrome (OR, 2.16; 95% CI, 1.30-3.60) and myeloma or plasmacytoma (OR, 1.53; 95% CI, 1.04-2.26). Lung cancer was also significantly associated with higher COVID-19–related mortality (OR, 1.58; 95% CI, 1.11-2.25). No association between higher mortality and receiving chemotherapy in the 4 weeks before COVID-19 diagnosis was observed after correcting for the crucial confounders of age, sex, and comorbidities. An association between lower mortality and receiving immunotherapy in the 4 weeks before COVID-19 diagnosis was observed (immunotherapy vs no cancer therapy: OR, 0.52; 95% CI, 0.31-0.86).Conclusions and Relevance The findings of this study of patients with active cancer suggest that recent SACT is not associated with inferior outcomes from COVID-19 infection. This has relevance for the care of patients with cancer requiring treatment, particularly in countries experiencing an increase in COVID-19 case numbers. Important differences in outcomes among patients with hematological and lung cancers were observed

Published
2022

32. Additional file 1 of Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

Author

So, Alfred Chung Pui, Karampera, Christina, Khan, Muhammad, Russell, Beth, Moss, Charlotte, Monroy-Iglesias, Maria J., Thillai, Kiruthikah, Josephs, Debra Hannah, Pintus, Elias, Rudman, Sarah, Van Hemelrijck, Mieke, Dolly, Saoirse, and Enting, Deborah

Subjects
endocrine system, endocrine system diseases, urogenital system, urologic and male genital diseases
Abstract

Additional file 1: Table S1. Patient demographics of prostate, renal, urothelial, and testicular cancer groups. Table S2. Oncological characteristics of prostate, renal, urothelial, and testicular cancer groups.

Published
2022
Full Text
View/download PDF

33. Using the Web for Name Authority Work.

Author

Russell, Beth M. and Spillane, Jodi Lynn

Abstract

Examines ways in which simple and effective Web searching can save catalogers time and money in the process of name authority work. Discusses the role of authority control; the NACO project and USMARC; and evaluating authority information found on the Web. (Author/LRW)

Published
2001

35. Impact of the COVID‐19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan

Author

Monroy‐Iglesias, Maria J., primary, Rai, Sonpreet, additional, Mistretta, Francesco A., additional, Roberts, Graham, additional, Dickinson, Harvey, additional, Russell, Beth, additional, Moss, Charlotte, additional, De Berardinis, Rita, additional, Ferro, Matteo, additional, Musi, Gennaro, additional, Brown, Christian, additional, Nair, Rajesh, additional, Thurairaja, Ramesh, additional, Fernando, Archana, additional, Cathcart, Paul, additional, Khan, Azhar, additional, Dasgupta, Prokar, additional, Malde, Sachin, additional, Hadijpavlou, Marios, additional, Dolly, Saoirse, additional, Haire, Kate, additional, Tagliabue, Marta, additional, de Cobelli, Ottavio, additional, Challacombe, Ben, additional, and Van Hemelrijck, Mieke, additional

Published
2022
Full Text
View/download PDF

36. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

Author

Russell, Beth, primary, Moss, Charlotte, additional, Tsotra, Eirini, additional, Gousis, Charalampos, additional, Josephs, Debra, additional, Enting, Deborah, additional, Karampera, Christina, additional, Khan, Muhammad, additional, Roca, Jose, additional, Sita-Lumsden, Ailsa, additional, Owczarczyk, Kasia, additional, Wylie, Harriet, additional, Haire, Anna, additional, Smith, Daniel, additional, Zaki, Kamarul, additional, Swampillai, Angela, additional, Lei, Mary, additional, Manik, Vishal, additional, Michalarea, Vasiliki, additional, Kristeleit, Rebecca, additional, Mera, Anca, additional, Sawyer, Elinor, additional, Flanders, Lucy, additional, De Francesco, Irene, additional, Papa, Sophie, additional, Ross, Paul, additional, Spicer, James, additional, Dann, Bill, additional, Jogia, Vikash, additional, Shaunak, Nisha, additional, Kristeleit, Hartmut, additional, Rigg, Anne, additional, Montes, Ana, additional, Van Hemelrijck, Mieke, additional, and Dolly, Saoirse, additional

Published
2022
Full Text
View/download PDF

38. Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer

Author

Russell, Beth, primary, Liedberg, Fredrik, additional, Hagberg, Oskar, additional, Ullén, Anders, additional, Söderkvist, Karin, additional, Ströck, Viveka, additional, Aljabery, Firas, additional, Gårdmark, Truls, additional, Jerlström, Tomas, additional, Sherif, Amir, additional, Holmberg, Lars, additional, Bryan, Richard T., additional, Enting, Deborah, additional, and Van Hemelrijck, Mieke, additional

Published
2021
Full Text
View/download PDF

40. Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review

Author

Chen, Miaoqi, primary, Rai, Ridesh, additional, Fox, Louis, additional, Moss, Charlotte Louise, additional, George, Gincy, additional, Karagiannis, Sophia N, additional, Enting, Deborah, additional, Joseph, Magdalene, additional, Peat, Nicola, additional, Russell, Beth, additional, and Van Hemelrijck, Mieke, additional

Published
2021
Full Text
View/download PDF

43. Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study

Author

Pinato, David J., Scotti, Lorenza, Gennari, Alessandra, Colomba-Blameble, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Aguilar-Company, Juan, Bower, Mark, Galazi, Myria, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Wuerstlein, Rachel, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona-García, M. Carmen, Sng, Christopher CT., Tondini, Carlo, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi-Gonzalez, Nadia, Felip, Eudald, Roqué Lloveras, Ariadna, Lee, Alvin J.X., Newsom-Davis, Thomas, Sharkey, Rachel, Chung, Chris, García-Illescas, David, Reyes, Roxana, Sophia Wong, Yien Ning, Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, Van Hemelrijck, Mieke, Diamantis, Nikolaos, and Cortellini, Alessio

Subjects
Europe, SARS-CoV-2, COVID-19, cancer, UK, Mortality, Original Research
Abstract

Background Despite high contagiousness and rapid spread, SARS-CoV-2 has led to heterogeneous outcomes across affected nations. Within Europe, the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100.000 as of January 2021. We aimed to compare the national impact of COVID-19 on the risk of death in UK cancer patients versus those in continental Europe (EU). Methods We performed a retrospective analysis of the OnCovid study database, a European registry of cancer patients consecutively diagnosed with COVID-19 in 27 centres from February 27 to September 10, 2020. We analysed case fatality rates and risk of death at 30 days and 6 months stratified by region of origin (UK versus EU). We compared patient characteristics at baseline, including oncological and COVID-19 specific therapy across UK and EU cohorts and evaluated the association of these factors with the risk adverse outcome in multivariable Cox regression models. Findings Compared to EU (n=924), UK patients (n=468) were characterised by higher case fatality rates (40.38% versus 26.5%, p

Published
2021

44. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience

Author

So, Alfred Chung Pui, primary, McGrath, Harriet, additional, Ting, Jonathan, additional, Srikandarajah, Krishnie, additional, Germanou, Styliani, additional, Moss, Charlotte, additional, Russell, Beth, additional, Monroy-Iglesias, Maria, additional, Dolly, Saoirse, additional, Irshad, Sheeba, additional, Van Hemelrijck, Mieke, additional, and Enting, Deborah, additional

Published
2021
Full Text
View/download PDF

45. The importance of patient and public involvement in cancer research: time to create a new job profile

Author

Van Hemelrijck, Mieke, primary, Peters, Vivienne, additional, Loong, John F, additional, Russell, Beth, additional, Fox, Louis, additional, Wylie, Harriet, additional, Santaolalla, Aida, additional, Beyer, Katharina, additional, Rammant, Elke, additional, Lin, E, additional, Haire, Anna, additional, Moss, Charlotte, additional, and Green, Saran, additional

Published
2021
Full Text
View/download PDF

46. Abstract 701: The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection as quantified by the OnCovid Inflammatory Score

Author

Dettorre, Gino M., primary, Dolly, Saoirse, additional, Loizidou, Angela, additional, Chester, John, additional, Jackson, Amanda, additional, Mukherjee, Uma, additional, Zambelli, Alberto, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sng, Christopher C., additional, Salazar, Ramon, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Mesia, Ricard, additional, Sita-Lumsden, Ailsa, additional, Seguí, Elia, additional, Biello, Federica, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Seeva, Pavetha, additional, Rizzo, Gianpiero, additional, Libertini, Michela, additional, Maconi, Antonio, additional, Moss, Charlotte, additional, Tabernero, Josep, additional, Russell, Beth, additional, Harbeck, Nadia, additional, Vincenzi, Bruno, additional, Bertulli, Rossella, additional, Ottaviani, Diego, additional, Liñan, Raquel, additional, Marrari, Andrea, additional, Carmona-García, M. Carmen, additional, Chopra, Neha, additional, Tondini, Carlo, additional, Mirallas, Oriol, additional, Tovazzi, Valeria, additional, Fotia, Vittoria, additional, Cruz, Claudia Andrea, additional, Saoudi-Gonzalez, Nadia, additional, Felip, Eudald, additional, Roqué, Ariadna, additional, Lee, Alvin J., additional, Newsom-Davis, Thomas, additional, Patriarca, Andrea, additional, Rimassa, Lorenza, additional, Santoro, Armando, additional, Gennari, Alessandra, additional, Diamantis, Nikolaos, additional, and Pinato, David J., additional

Published
2021
Full Text
View/download PDF

48. sj-pdf-1-inq-10.1177_00469580211030217 – Supplemental material for Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience

Author

Bessa, Agustina, Bosco, Cecilia, Cahill, Fidelma, Russell, Beth, Fox, Louis, Moss, Charlotte, Wylie, Harriet, Haire, Anna, Green, Saran, Enting, Deborah, Khan, Shamim, Nair, Rajesh, Thurairaja, Ramesh, Chatterton, Kathryn, Amery, Suzanne, Peat, Nicola, Smith, Sue, Spear, Stuart, Bryan, Richard T, Frodsham, Leila, Burke, Danny, Rigby, Jeannie, Makaroff, Lydia, Kelly, Phil, Costin, Melanie, Häggström, Christel, and Van Hemelrijck, Mieke

Subjects
111099 Nursing not elsewhere classified, FOS: Health sciences
Abstract

Supplemental material, sj-pdf-1-inq-10.1177_00469580211030217 for Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience by Agustina Bessa, Cecilia Bosco, Fidelma Cahill, Beth Russell, Louis Fox, Charlotte Moss, Harriet Wylie, Anna Haire, Saran Green, Deborah Enting, Shamim Khan, Rajesh Nair, Ramesh Thurairaja, Kathryn Chatterton, Suzanne Amery, Nicola Peat, Sue Smith, Stuart Spear, Richard T Bryan, Leila Frodsham, Danny Burke, Jeannie Rigby, Lydia Makaroff, Phil Kelly, Melanie Costin, Christel Häggström and Mieke Van Hemelrijck in INQUIRY: The Journal of Health Care Organization, Provision, and Financing

Published
2021
Full Text
View/download PDF

49. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Author

Dettorre, Gino M., Dolly, Saoirse, Loizidou, Angela, Chester, John, Jackson, Amanda, Mukherjee, Uma, Zambelli, Alberto, Aguilar Company, Juan, Bower, Mark, Sng, Christopher C. T., Salazar Soler, Ramón, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Seeva, Pavetha, Rizzo, Gianpiero, Libertini, Michela, Maconi, Antonio, Moss, Charlotte, Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona García, M. Carmen, Chopra, Neha, Tondini, Carlo Alberto, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi González, Nadia, Felip, Eudald, Roqué, Ariadna, Lee, Alvin J. X., Newsom-Davis, Tom, García Illescas, David, Reyes, Roxana, Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Marco Hernández, Javier, Ruiz Camps, Isabel, Patriarca, Andrea, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Santoro, Armando, Prat Aparicio, Aleix, Gennari, Alessandra, Van Hemelrijck, Mieke, Tabernero Caturla, Josep, Diamantis, Nikolaos, Pinato, David J., OnCovid study group, Dettorre, G. M., Dolly, S., Loizidou, A., Chester, J., Jackson, A., Mukherjee, U., Zambelli, A., Aguilar-Company, J., Bower, M., Sng, C. C. T., Salazar, R., Bertuzzi, A., Brunet, J., Mesia, R., Sita-Lumsden, A., Segui, E., Biello, F., Generali, D., Grisanti, S., Seeva, P., Rizzo, G., Libertini, M., Maconi, A., Moss, C., Russell, B., Harbeck, N., Vincenzi, B., Bertulli, R., Ottaviani, D., Linan, R., Marrari, A., Carmen Carmona-Garcia, M., Chopra, N., Tondini, C. A., Mirallas, O., Tovazzi, V., Fotia, V., Cruz, C. A., Saoudi-Gonzalez, N., Felip, E., Roque, A., Lee, A. J. X., Newsom-Davis, T., Garcia-Illescas, D., Reyes, R., Wong, Y. N. S., Ferrante, D., Scotti, L., Marco-Hernandez, J., Ruiz-Camps, I., Patriarca, A., Rimassa, L., Chiudinelli, L., Franchi, M., Santoro, A., Prat, A., Gennari, A., Van Hemelrijck, M., Tabernero, J., Diamantis, N., Pinato, D. J., Wellcome Trust, Institut Català de la Salut, [Dettorre GM] Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. [Dolly S] Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust (GSTT), London, UK. [Loizidou A] Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. [Chester J] Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK. Medical Oncology, Velindre Cancer Centre, Cardiff, UK. [Jackson A] Clinical Trials, Velindre Cancer Centre, Cardiff, UK. [Mukherjee U] Medical Oncology, Barts Health NHS Trust, London, UK. [Aguilar-Company J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Mirallas O, Saoudi-Gonzalez N, García-Illescas D] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, Comorbidity, Systemic inflammation, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], COVID-19 Testing, 0302 clinical medicine, Neoplasms, Immunotherapy Biomarkers, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], 80 and over, Immunology and Allergy, Medicine, Hypoalbuminemia, Young adult, Càncer, Multivariate Analysi, RC254-282, COVID-19 (Malaltia) - Complicacions, Cancer, Aged, 80 and over, OnCovid study group, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Middle Aged, Prognosis, Inflamació, Systemic Inflammatory Response Syndrome, 030220 oncology & carcinogenesis, Cohort, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome [DISEASES], Molecular Medicine, Female, medicine.symptom, Life Sciences & Biomedicine, Human, Adult, medicine.medical_specialty, Prognosi, Càncer - Epidemiologia, Immunology, neoplasias [ENFERMEDADES], inflammation mediator, Young Adult, 03 medical and health sciences, Internal medicine, Humans, afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica [ENFERMEDADES], Aged, Pharmacology, Science & Technology, business.industry, SARS-CoV-2, COVID-19, medicine.disease, inflammation, inflammation mediators, Blood Cell Count, Multivariate Analysis, Neoplasms [DISEASES], Systemic inflammatory response syndrome, 030104 developmental biology, Neoplasm, Lymphocytopenia, business, Other subheadings::Other subheadings::/complications [Other subheadings]
Abstract

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamació; Mediadors d'inflamació Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamación; Mediadores de la inflamación Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammation; Inflammation mediators Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study. Methods In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets. Results We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results